Human TLR2 Alexa Fluor® 488-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB2616G
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Accession # O60603
Specificity
Clonality
Host
Isotype
Applications for Human TLR2 Alexa Fluor® 488-conjugated Antibody
Flow Cytometry
Sample: Human whole blood monocytes
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: TLR2
Human toll-like receptor (TLR) family includes ten members that activate the innate immune response via an ability to recognize molecular structures found in a variety of microbial pathogens (1‑3). All TLR family members are type I transmembrane proteins with a large number of extracellular leucine-rich repeats (LRRs) and a cytoplasmic Toll/IL-1 receptor (TIR) domain. Human TLR2 is synthesized as a 784 amino acid (aa) precursor (2) that contains a signal sequence (aa 1-18), an extracellular domain (aa 19-588) with approximately 20 LRRs, a transmembrane segment (aa 589-609), and a cytoplasmic TIR domain (aa 610-784). The receptor is expressed on a number of cell types including monocytes, dendritic cells, neutrophils, B cells endothelial cells, and hepatocytes (1, 2, 4). TLR2 functions as part of a heterodimeric complex with either TLR1 or TLR6, and possibly other co-receptors (1). These complexes recognize lipoproteins and glycolipids from gram-positive and gram-negative bacteria as well as mycoplasma and yeast. TLR2/TLR1 heterodimers bind triacylated lipopeptides, while the TLR2/TLR6 heterodimer preferentially recognizes diacylated lipopeptides (5). Upon ligand recognition, TLR2 delivers an activating signal via the associated adapter molecules, MyD88 and TIRAP (1, 6). TLR2 signaling results in dendritic cell maturation characterized by increased surface expression of class II MHC and the T cell costimulators, CD80 and CD86 (1, 2). Activation via TLR2 also results in production of a number of pro-inflammatory cytokines including TNF-alpha, IL-2, IL-6, IL-12, and MIP-2 (1-3).
References
- Wetzler, L. (2003) Vaccine 21:S2/55.
- Kirschning, C. and R. Schumann (2002) Curr. Top. microbiol. Immunol. 270:121.
- Netea, M. et al. (2004) J. Leukoc. Biol. 75:749.
- Flo, T. et al. (2001) J. Leukoc. Biol. 69:474.
- Akira, S. (2003) Curr. Opin. Immunol. 15:5.
- Yamamoto, M. et al. (2002) Nature 420:324.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional TLR2 Products
Product Documents for Human TLR2 Alexa Fluor® 488-conjugated Antibody
Product Specific Notices for Human TLR2 Alexa Fluor® 488-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only